Introduction
Cancer is the second leadingc ause of death in the USA and many European countries. [1] Whereas breast canceri sa mong the five most common types of cancers,t he five-year survival rate is one of the lowest of all cancers. [2] [3] [4] Also, pancreatic cancer is currently one of the deadliest of the solid malignancies, [5] and surgery remains the only optionf or cure. [6] Another example of major canceri sm elanoma. [7] An eed, therefore, exists for the discovery of novel compounds that are more effective but less toxic for the treatment of these cancers.
It has long been recognized that inflammationi sr elated to cancer,a nd strong correlation between the presence of inflammation and the development of precancerous lesionsh as been established. [8] One novel approacht ot he treatment of cancer lies in the discoveryo fn ew compoundsw ith an ew mechanism of action that are efficacious in reducing tumor size and/or the spread of metastasis and that can also reduce inflammation. These compounds, which simultaneously exhibit significant anticancera nd anti-inflammatory properties, offer a potentialt wo-prongeda pproacht hat targets both genetically unstablet umor cells (high mutation rate and subsequentr esistance to chemotherapy) and genetically normalc ells present in inflamed tissue. This two-pronged approach to the treatment of canceri sm ade more compelling by the increasing awareness that al ink exists between chronic inflammationa nd the subsequentd evelopment of cancer.
[9] It has been shown that chronic inflammation is associated with the development of numerous human cancers. [10] For example, markerso fasystemic inflammatory response have prognostic significance in advanced, inoperable pancreatic cancer, [11] and inflammatory processes have emerged as key mediators of breast cancer development and progression. [12] Inflammatory cytokines such as tumor necrosis factor (TNF-a), [13] IL-1, IL-6, [14] and MCP-1 [15] have been shown to be involved in all stages of the malignant process. In ab reast, [16] prostate, [17] and melanoma [18] cancer study, both serum TNF-a and IL-6 correlatedw ith the extent of the disease. Other inflammatorym ediators, such as prostaglandins and leukotrienes, have also been reported to play ar ole in the development and progression of several cancers, including breast, [19] melanoma, [20] and pancreatic [21] cancers. 1,3,5-Triazine compounds have been studied extensively and are the subject of many reviews. [22] The triazine scaffold has been exploited for the design of biologically relevantm olecules with broad biomedical value as therapeutics. [23] For example,t hese compounds possess potent antiprotozoa, [24] antiviral, [25] fungicidal, [22] insecticidal,b actericidal, [26] herbicidal, [27] antimicrobial, [28] and antimalarial [29] activities. In addition, trisubstituted triazines have been shown to display protein A Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activitiesw ere explored.S tructure-activity relationship studies demonstrated the importance of the aminopentyl chain, the 3-or 4-fluorophenylaniline component, and the presence of at least one substituent, such as at yramine moiety,a ttached directly to the triazine ring as essential for good activity. ( 10) , displayed moderate and significant in vitro and in vivo dual activities, respectively,a nd address the molecular link between inflammationa nd cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers an ovel approach to the treatment of inflammation andc ancer.
mimeticp roperties for the treatment of autoimmune diseases.
[30] As parto fo ur autoimmune diseases program, small molecules were examined as potential anticancer agents. Ar ecent review describes the versatile bioactivities of 1,3,5-triazine derivatives as potentiala ntitumor compounds. [31] The reasonsf or selectingt he 1,3,5-triazine scaffold were threefold:1 )1,3,5-triazines are monocyclic, symmetrical molecules and have been utilized as promising scaffolds for their versatile biological potential; [32] 2) the presenceo ft hree nitrogen atoms in the 1,3,5-triazine core can inherently impart polarity to the whole molecule, and the partition coefficient (c log P)v alues of the designed compounds can be about 2o rl ower;3 )trifunctionalized 1,3,5-triazines are ideal modulars caffolds for generating libraries. These molecules may demonstrate remarkable pharmacokinetics and oral bioavailability with additional modifications. In this paper,t he synthesis and anticancer anda nti-inflammatory activities of trisubstituted triazines, as exemplifiedb yt he general structure 1,are reported.
Results and Discussion
As part of an effort towards the discovery of novel therapeutics for the treatment of autoimmune diseases,asearch was initiated to discover small molecules that possessa nti-inflammatory activity.Itwasreportedt hat fluorophenylaminotriazine derivatives possessa nti-inflammatory activity (kinase inhibitors, [33] EGFR inhibitors, [34] and glycosidase modulators [35] ). Considering that we synthesized and tested in-house many fluorophenylamino-4,6-disubstituted 1,3,5-triazines [28] as protein Am imetics and as antimicrobiala gents, an umber of these compounds were selected and screened on the basis of general structure 1.
The starting materialf or these compounds was cyanuric chloride. This is an inexpensive commercially available reagent, which makes its use attractive. The ease of displacement of the chlorine atoms in cyanuric chloride by various nucleophiles enhances the utility of this reagent for the preparation of mono-, di-, and trisubstituted 1,3,5-triazines at controlled temperatures. [36] The general synthetic sequence for the preparation of triazine compounds is outlined in Scheme1.I ti llustrates the route employedf or the preparation of trisubstituted triazine 5,f or which the key intermediate was dichlorotriazine 2.C ompound 5 was prepared by two differentr outes. The first route involved the reaction of cyanuricc hloride with fluoroaniline at À10 8Ci nt he presence of sodium bicarbonatet og ive dichlorotriazine intermediate 2.T his reaction proceeded in excellent yield (> 95 %) and was general for different aniline derivatives. [30, 37] Aminoalkylaminesw ere then added in the presence of ab ase to afford triazine 3 in high yield (90 %). This compound was then treatedw ith different aryl-and aralkylamines to give products 5.R oute 2d emonstrates the preparation of dichlorotriazine intermediate 2 as in route 1, followed first by the reaction with aryl-and aralkylamines to give 4 and then by the addition of aminoalkylaminesa t1 30 8Cf or 10 min by using microwavei rradiation to afford compound 5.T he last step was the removal of the protecting groups.
These compounds were evaluated for their anti-inflammatory activity by using inhibition of TNF-a productionb yl ipopolysaccharide (LPS)-stimulated J774A.1 cells (murinem acrophages). At otal of 15 compounds were chosen upon which to define as tructure-activity relationship for a2 -(3-or 4-fluorophenylamino)-4, 2 ) n NH, n = 0-2], and the thirdg roup was held constant as a3 -o r4 -fluorophenylamine group. Ta ble 1i llustrates the variation of these substituents and demonstrates in vitro the effecto fa nalogues of 1 on tumor necrosis factor (TNF-a)p roduction,a sm easured by ELISA (enzyme-linked immunosorbent assay) by using J774A.1 cells stimulated by LPS. J774A.1 cells were cultured in the presence or absence of LPS and the compound. The cells werepretreated with the compounds 1h prior to LPS stimulation. The supernatants were collected to determine the concentration of TNF-a by ELISA. The data were analyzed, and the concentration of compound that inhibited 50 %o fT NF-a production (IC 50 )w as calculated. Prior work indicated the importance of the length of the carbon chain (n-pentyl)b etween the amine groups.I nf act, ad ecrease in the lengtho ft he chain by three carbon atoms (as in compound 12)o rb yo ne carbon atom (as in compounds 17 and 23)r educed the activity.H owever,h o- mologation of the alkyl chain with ao ne-carbon spacerc hain length (as in compound 24)r esulted in somea ctivity but also some toxicity.S imilarly,r igidifying the six-carbon chain and keeping the terminal amine function (as in compound 25) gave some toxicity. However,i ntroducing ah eteroatom in the chain (asi nc ompound 21)o ri ncreasing the rigidity of the chain by forming ar ing with the primary amine function( as in compound 22)l ed to ad rop in activity.I tw as observed that inhibition of TNF-a waso btained with triazine compounds containing at yramine moiety,f or example, compounds 6, 10, and 11.H owever,s ubstitution of the alkyl chain of the tyramine unit with ah ydroxy group, as in compound 18,o racarboxylate group, as in compound 19,r esulted in al oss of activity.C hanging the tyraminem oiety to an arylsulfonamide unit, as in 16,o rabenzylamine, as in 20,a lso resulted in al oss of activity.S imilarly,c ompounds 13, 9,a nd 8,i nw hich the hydroxy group of the tyramine unit was replaced with an amide group, an amine, and a N,N-dimethylsulfonamide, displayed lower activity.I nc ontrast, corresponding carboxylic ester 14 and sulfonamides 7 and 15 showedw eaker activity than compounds 6 and 10.A lso, the correcta cidity of the phenol group in the tyramine unit was important for the activity of the triazine compounds. For example, adding an ortho electron-donating substituent such as am ethoxy group to give compound 26 made the phenol less acidic and not active. In contrast, adding an ortho electron-withdrawing substituent such as a chlorine atom to give compound 27 resulted in some activity but also some toxicity. In general, compound 10 in which the triazine ring is substituted with a4 -fluoroaniline, tyramine, and ap entylamine chain resulted in good activity relative to that observed for corresponding 3-fluoroanilines 6 and 11.
On the basis of the above results, three triazine compounds demonstrated inhibition of TNF-a production. Compounds 6 and 7 showedm oderate inhibition, whereas triazine 10 gave good TNF-a inhibition. To confirm the anti-inflammatory activity of triazine derivative 10,wes tudied the in vitro effect of this compound on the production of prostaglandin E2 (PGE2)i n LPS-stimulated J774A.1 cells. The results are showni nF igure 1.
LPS-stimulated J774A.1 cells produce PGE2, abioactive lipid associated with inflammation and cancer. Compound 10 was demonstrated to inhibit PGE2 production in stimulated J774A.1 cells with an IC 50 of 1.82 mm.I tw as next demonstrated that the in vitro activity of 7 and 10 would translatei nto moderate and significant in vivo activity,r espectively,i narelevant model of inflammation. Therefore,c ompounds 7 and 10 were assessedi na nL PS-induced inflammation air-pouch modeli n rats. This animal model has widely been used to study the anti-inflammatory activity of test compounds in efficacy studies. Upon injection withL PS, the air-pouch produces an inflammatoryr esponse characterized by the infiltrationo fi nflammatory cells and the productiono fi nflammation factors, such as TNF-a and PGE2. Figure 2r epresents the effect of the intravenous administration of the two compounds on TNF-a production induced by LPS (2 ha fter induction) in the air-pouch rat model. Compound 10 significantly inhibited TNF-a production induced by LPS. As expected and on the basis of the above results, compound 7 had some effect on the concentrationo fT NF-a in the exudates 2h post-LPS induction. Also, similare ffects wereo btained by intravenousa dministration of compounds 7 and 10 on TNF-a production induced by LPS (12 h) in the air-pouch rat model ( Figure 3 ).
Another experiment was performed to confirm the anti-inflammatory activity of compound 10 compared to that of compound 7.F igure 4r epresents the effect of the intravenous administration of compound 7 or 10 on PGE2 production induced by LPS (12 ha fter induction) in an air-pouch rat model. Compound 10 and indomethacin significantly inhibited PGE2 production induced by LPS. However,c ompound 7 demonstrated aw eak and nonsignificant effect on PGE2 production. The next step was to examine the anticancer activity of the two bestc ompounds, 6 and the lead 10,i ni nvitro and in vivo models. Cell proliferation, enhanced cell motility,c ell adhesion, proteolytic degradationo ft he extracellular matrix,a nd cell migration are inter-relatedp rocesses that are responsible for the invasiona nd metastasis of cancer. In prostatec ancer,androgen independence and bone metastasis are lethal complications in patients.T he first in vitro experiment wast oe valuate the effect of compound 10 on PC-3 prostate cancer cell line proliferation by using DNA synthesis by 3 H-thymidine incorporation and the cell cycle. This compound reduced PC-3 cell proliferation with an IC 50 of 43.3 mm at 24 h( Figure5)a nd 72 hb ut exhibited no effect on the cell cycle below 20 mm.W ed emonstrated,f rom cell-cyclee xperiments ( Figure 5) , that there was cell-cyclea rrest in the G0/G1 phase. No increase in the sub G0/ G1 phase waso bserved, and hence, no apoptosis occurred at compound concentrations of 40 and 80 mm.T herefore, compound 10 at ac oncentration of 10 mm was used fort he remaining in vitro experiments. In as econd experiment, it was desired to demonstrate the effect of the compounds on epidermal growth factor (EGF)-induced migration of the PC-3 prostatec ancerc ell line in an in vitro scratch woundh ealing assay.Amigration assay was used to assess cell mobility in two dimensions.C onfluent cells were quiesced by starvation and mitomycin Ct reatment to prevent the confounding issue of cell proliferation.C ells were incubated in the presence or absence of EGF and 6 or 10 for 24 h. Photographs were taken at 24 h. Figure6represents the effects of EGF and compounds 6 and 10 on PC-3 cell migration or invasion. EGF promotes the migration or invasion of PC-3 cells treated with mitomycin compared to ac ontrol (withoutg rowth factor). The addition of differentc oncentrationso f10 to the cell culture resulted in inhibition of the EGF-induced PC-3 migration or invasion ( Figure 6 ). However,a se xpected, compound 6 performed less well than compound 10 ( Figure 6 ). The addition of different concentrations of compound 6 to the cell culturep roduced partial inhibition of the EGF-induced PC-3 migration or invasion after culture for 24 h.
Compound 10 showed in vitro activity on PC-3 prostate cancer,w hich is am odel that involves inflammation. The next step was to determine if this activity translated into anticancer/anti-inflammatory mousem odels. The first experiment was to study the antitumor effects of compound 10 on primary tumorP 815 cells. Thisc ell line has been used extensively as a cancer model to establish arelationship between the tumor-induced local, regional, and systemic increase of proinflammatory mediators and progression of tumors in vivo.
[38] Figure 7 shows the effect of the oral administration (PO) of triazine derivative 10 (50 mg kg
À1
)a nd acetylsalicylica cid (positive control, 50 mg kg
)o np rimary tumor P815 cells. Compound 10 induced as ignificant reduction T/C (mean relative tumor volumeo ft reated group/mean relative tumor volume of control group) between 40 and 50 %o ft umor growth.F urthermore,t he efficacyo ft his compound was comparable to that of the gold standard,s oluble acetylsalicylicacid (lysine salt).
To validate this observation, another in vivo experiment was performed to demonstrate the effect of the oral administration of compound 10 (25 mg kg
)o np rimary melanoma tumor B16F10 cells. Triazine 10 induced as ignificant reduction (T/C < 40 %, p = 0.001) in the tumor volume compared to the control, Cytoxan (cyclophosphamide, 100 mg kg À1 ) ( Figure 8 ). Also, additional experiments were undertaken with other types of cancer.F igure 9s hows the antitumore fficacy of com- The fact that compound 10 showed similara nticancer and anti-inflammatory activitiess uggests that there is ad irect relationship betweent he two diseases.I ndeed, it was reported that af ew smallm olecules [39] and severaln atural products [40] exhibitedastrong correlation between anti-inflammatory and anticancer activities. )o fc ompound 10 at days 11,1 2, 13, 15, 18, and 20. Tumors were palpable7t o1 0days postinoculation. In both types of administration, compound 10 induced significant (p < 0.05) inhibition of tumor volume with T/C between 35 and 57 %, which is comparable to cyclophosphamide, which induces significant (p < 0.04) inhibition of tumor volumew ith T/C between 33 and 59 %.
We then sought to demonstrate if compound 10 could inhibit other types of cancer,e specially those that spread (metastasize) to other parts of the body.F igure 12 shows the antitumor efficacy of the oral administration of compound 10 (50 mg kg The mechanism by whichmost-active compound 10 demonstrates anti-inflammatory and anticancerp roperties in vivo is under investigation. To address this issue, different experiments were undertaken to identify the target. Compound 10 inhibits TNF-a synthesis and activity withouta ffecting TNF-a bindingt oi ts receptors (TNF-RI and TNF-RII). It inhibits PGE2 production [41] with no effect on Cox-1 and Cox-2 activity.I th as weak in vitro cytotoxicity (IC 50 > 10 mm)o nN HDF (normal human dermal fibroblasts), HUVEC (human umbilical vein endothelialc ells), PC-3, K562, P815, andr estingP BML (peripheral blood mononuclear leukocytes) (Table2). Even though compound 10 showeds ome toxicity in vitro on normalc ells, the in vivo air-pouch rat model showed that this compound inhibited both TNF-a and PGE2. These results indicatet he effect of compound 10 on proinflammatory cytokines that can affect tumor growth. In fact, in all types of cancers studied in vivo, we observed no regression of tumors but as low down of growth, which is an indication that compounds 6, 7,a nd 10 affect cancerc ell proliferation but do not kill the cells directly. It is most likely scaffold linked/dependent. Furthermore, compound 10 had no effect on PLA2, 5-Lox, and 15-Lox enzymatic activities or modulationo fi NOS expression. On PC-3 prostate cancer cells, compound 10 (20 mm)i nduced cell-cycleb lock in G1. Compound 10 had no effect on microtubule polymerization.
Conclusions
Low-molecular-weight synthetic molecules 1 with ag eneral 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activitiesw ere described. Basic structure-activity relationship studies demonstrated the importance of the 3-or 4-fluorophenylaniline group attached to the triazine ring, which played ar ole in the activity of these compounds.T wo lead triazines, 6 and 10,d isplayed both in vitro and in vivo dual activity at moderate and significant levels,r espectively,i na nticancer/anti-inflammatory models. Thisa ddresses the molecularl ink between inflammation and cancer.C ompound 10 demonstrated significant antitumor efficacy in severala nimal models, such as the breast DA-3 adenocarcinoma and human xenogeneic prostateP C-3 cancer models.T his was confirmed by the ability of compound 10 to inhibit PGE2 in vitro in stimulated J774 cell (murinem acrophage) andi nvivo (LPS-induced air-pouch assay). Also, compound 10 reduced PC-3 cell proliferation with an IC 50 of 20 mm by inducing cell-cycle arrest at the G0/G1 phase. In an in vitro model of wound healing, compound 10 inhibited PC-3 cell migration/invasion. This class of triazine compounds is new, safe, [42] and nontoxic [43] and offers an ovel approacht ot he treatment of inflammationa nd cancer.
Experimental Section GeneralM ethods
All HPLC chromatograms and mass spectra were recorded with an HP 1100 LC-MS Agilent instrument by using ad iode array detector. An analytical C18 column (75 4.6 mm, 5 mm) with ag radient of 1-40 %a cetonitrile/water containing 0.01 %t rifluoroacetic acid (TFA) in 6min and af low of 2mLmin À1 (method 1), an analytical C18 column (75 4.6 mm, 5 mm) with ag radient of 15-99 %a cetonitrile/water containing 0.01 %T FA in 6min and af low of 2mLmin Cyanuric chloride (10.0 g, 54.2 mmol) was added in small portions to ac ooled (À10 8C) mixture of water (50 mL) and acetone (50 mL). As olution of 3-fluoroaniline (5.2 mL, 54.2 mmol) in acetone (50 mL) was added slowly over 50 min, maintaining the temperature of the reaction below À5 8C. The mixture was then stirred at ambient temperature for 1h.T he pH of the mixture was adjusted from 2t o8with saturated aqueous sodium bicarbonate (200 mL), and stirring was continued for another 30 min. The precipitated solid was collected by filtration, washed with water,a nd dried in vacuo. This gave 2,4-dichloro-3-fluorophenylamino-1,3,5-triazine as aw hite solid (13. + ;H PLC (method 2): t R = 4.1 min. The product was used in the next step without further purification. This dichlorotriazine derivative (6.4 g, 24.7 mmol) was dissolved in THF (70 mL) at RT and was treated with asolution of 5-(tert-butoxycarbonylamino)pentylamine (7.5 g, 37.0 mmol) in am ixture of acetone (50 mL) and water (50 mL). The resulting solution was then treated with saturated aqueous sodium bicarbonate (70 mL). The mixture was stirred at RT for 2.5-3 h. The mixture was then concentrated in vacuo, and the residue was diluted with water and extracted with ethyl acetate. The combined organic extract was washed with saturated aqueous sodium chloride, 2 m aqueous HCl, saturated sodium chloride, saturated sodium bicarbonate, and sa- + ;H PLC (method 2): t R = 4.5 min. As olution of the monochlorotriazine (6.6 g, 15.6 mmol) in THF (300 mL) was treated with tyramine (6.4 g, 46.7 mmol) and triethylamine (77.7 mmol, 10.9 mL). The mixture was heated at 65-70 8Cf or 16-60 h, cooled to ambient temperature, and concentrated in vacuo. The residue was extracted with ethyl acetate and filtered. The filtrate was washed with 1 m aqueous HCl, saturated sodium chloride, saturated aqueous sodium bicarbonate, and saturated sodium chloride;d ried (magnesium sulfate/charcoal);f iltered through Celite diatomaceous earth;a nd concentrated in vacuo. The residue was then dissolved in ether (150 mL), and this solution was added dropwise to hexane (1.4 L) with vigorous stirring. The precipitated solid was collected by filtration and dried in vacuo to yield the tri(amino-substituted) 1,3,5-triazine derivative as an offwhite solid (6. + ;H PLC (method 2): t R = 2.9 min. As olution of the tert-butoxycarbonyl (Boc)-protected compound (6.5 g, 12.4 mmol) in 4 m HCl/1,4-dioxane (100 mL) and water (10 mL) was stirred at RT for 2h.T he solvents and the excess amount of acid were evaporated in vacuo, and the trace amounts of water were removed by co-evaporation (2 )w ith 2-propanol (25 mL). The dried residue was dissolved in 2-propanol (25 mL), and the solution was added dropwise to ether (450 mL) with vigorous stirring. The precipitated solid was collected by filtration, dried in vacuo, and then dissolved in pyrogen-free water (800 mL), filtered (0.22 mm), and lyophilized to give deprotected compound 6 as an off-white solid (5. This compound was prepared by using the same method as that outlined for compound 6 by using 4-(2-aminoethyl)benzenesulfonamide instead of tyramine. White solid;7 7% yield;m .p. 145-147 8C; + ;H PLC (method 2): t R = 3.7 min. As olution of the monochlorotriazine (15.0 g, 41.8 mmol) and 1,5-diaminopentane (24.5 mL, 209 mmol) in tetrahydrofuran (125 mL) and methanol (60 mL) was divided into nine portions. Each portion was heated in ac hemistry microwave apparatus at 130 8Cf or 10 min. The portions were then recombined and concentrated in vacuo, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with water and saturated sodium chloride and then extracted with 2 m aqueous HCl. The aqueous extract was treated with ethyl acetate and then saturated aqueous sodium bicarbonate. The precipitate was extracted with ethyl acetate, and the combined extract was washed with saturated sodium chloride, dried (magnesium sulfate/charcoal), filtered through Celite diatomaceous earth, and concentrated in vacuo. The residue was dissolved in methanol (300 mL), and the solution was treated with 1 m HCl in ether (60 mL). The solution was then concentrated in vacuo. The residue was dissolved in hot 2-propanol (150 mL), and this solution was added dropwise to ether (1.5 L) with vigorous stirring. The precipitated solid was collected by filtration, dried in vacuo, and then dissolved in pyrogen-free water (1.6 L), filtered (0.22 mm), and lyophilized to give compound 10 as the hydrochloride salt (14. + ;H PLC (method 2): t R = 3.7 min. As olution of the phthaloyl-protected, N,N-dimethyl compound (11.3 g, 31.5 mmol) and hydrazine hydrate (4.6 mL, 44.6 mmol) in 95 %e thanol (125 mL) was heated at reflux for 2h.T he white solid that formed was removed by filtration and was washed with ethanol. The filtrate and washings were combined, and the solution was concentrated in vacuo. The solid that formed was removed by filtration and was washed with ethanol. This procedure was repeated (3 ), and the final filtrate was concentrated to dryness in vacuo. The solid was extracted with ethyl acetate. The extracts were concentrated in vacuo to give the free amine as ay ellow oil (4. This compound was prepared according to the procedure outlined for compound 6 by using N-(5-aminopentyl)acetamide instead of 5-(tert-butoxycarbonylamino)pentylamine. Orange solid (37 Aminoethylamino)-6-(4-fluorophenylamino)-1,3 This compound was prepared according to the procedure outlined for compound 6 by using methyl 4-(2-aminoethyl)benzoate instead of tyramine. ized tumors in 6-to-8-week-old C57BL/6 mice. The animals were then serially monitored by manual palpation for evidence of tumor.M ice were then treated every day with oral administration of vehicle (negative control) or compound (50 mg kg
4-{2-[4-(2-

À1
)a nd with intraperitoneal injection of gemcitabine (50 mg kg À1 )a td ay 6a nd day 12. Mice were sacrificed at day 35. Serial tumor volume was obtained by bi-dimensional diameter measurements with calipers by using Equation (1) . Tumors were palpable, in general, 3days to 5days postinoculation.
Antitumor Effects of Compounds on aP rimary DA-3 Breast Tumor
The syngeneic tumor DMBA3 (DA-3, breast carcinoma model) arose from ap reneoplastic lesion treated with 7,12-dimethylbenzanthracene in female BALB/c mice. DA-3 cells were grown as monolayer cultures in plastic flasks in RPMI-1640 containing 0.1 mm nonessential amino acids, 0.1 mm sodium pyruvate, and 2mml -glutamine. This was further supplemented with 50 mm 2-mercaptoethanol and 10 %f etal bovine serum. The DA-3 tumors were serially passaged in vivo by intradermal inoculation of 5 10 5 viable tumor cells (50 mL) to produce localized tumors in 6-to-8-week-old BALB/c mice. The animals were then serially monitored by manual palpation for evidence of tumor.M ice were treated at days 11 and 18 with cyclophosphamide (100 mg kg
À1
,I Vi njection) and by intravenous treatment at days 11,1 2, 13, 15, 18, and 20 with compound. Mice were sacrificed at day 18. Serial tumor volume was obtained by bi-dimensional diameter measurements with calipers by using Equation (1) . Tumors were palpable, in general, 7days to 10 days postinoculation.
Antitumor Effects of Compounds on Xenograft Human Prostate PC-3 Tumor
The xenogenic human prostate tumor PC-3 was obtained from ATCC (CRL1435). PC-3 cells were grown in RPMI-1640 containing 10 %f etal bovine serum. At day 0, viable PC-3 (1.5 to 2 10 6 ,5 0mL) cells were intradermally injected to produce localized tumors in 6-to-8-week-old male CD1 nu/nu mice. The animals were then serially monitored by manual palpation for evidence of tumor.W hen the tumors reached as atisfactory volume, mice were randomized and then treated four,t hree, and three times aw eek for the first, second, and third weeks, respectively,w ith intravenous injection of vehicle (negative control), cyclophosphamide (positive control, 100 mg kg À1 ), or oral administration of compound (50 mg kg
À1
). Mice were sacrificed at day 50. Serial tumor volume was obtained by bi-dimensional diameter measurements with calipers by using Equation (1) .
